Prognostic Biomarkers in Squamous Cell Carcinoma of the Anus: a Systematic Review

Overview

Journal Br J Cancer

Specialty Oncology

Date 2010 Nov 11

PMID 21063399

Citations 21

Authors

T Lampejo

D Kavanagh

J Clark

R Goldin

M Osborn

P Ziprin

S Cleator

Affiliations

Soon will be listed here.

Abstract

Background: recent decades have seen combination chemoradiotherapy become the standard treatment for anal squamous cell carcinoma (SCC). However, the burden of this disease continues to rise, with only 10% of patients with metastatic disease surviving >2 years. Further insight into tumour characteristics and molecular biology may identify novel therapeutic targets. This systematic review examines current prognostic markers in SCC of the anus.

Methods: an extensive literature search was performed to identify studies reporting on biomarkers in anal cancer in the context of clinical outcome following treatment primarily with chemoradiotherapy.

Results: in all, 21 studies were included. A total of 29 biomarkers were studied belonging to 9 different functional classes. Of these biomarkers, 13 were found to have an association with outcome in at least one study. The tumour-suppressor genes p53 and p21 were the only markers shown to be of prognostic value in more than one study.

Conclusions: an array of biomarkers have been identified that correlate with survival following chemoradiotherapy in anal cancer. However, investigators are yet to identify a biomarker that has the ability to consistently predict outcome in this disease. Further studies are needed to elucidate whether these candidate biomarkers demonstrate their optimum value when they serve as targets for new therapeutic strategies.

Citing Articles

HPV status and immunohistochemical analysis of p16, p53 and PD‑L1 expression as prognostic biomarkers in patients with squamous cell anal cancer receiving definitive radiotherapy/chemoradiotherapy.

Balci Topuz B, Sert F, Sezak M, Soylu M, Yalman D, Ozkok S Oncol Lett. 2024; 28(2):395.

PMID: 38966586 PMC: 11223008. DOI: 10.3892/ol.2024.14528.

Molecular biomarkers, network biomarkers, and dynamic network biomarkers for diagnosis and prediction of rare diseases.

Tang S, Yuan K, Chen L Fundam Res. 2024; 2(6):894-902.

PMID: 38933388 PMC: 11197705. DOI: 10.1016/j.fmre.2022.07.011.

Biomarkers in Anal Cancer: Current Status in Diagnosis, Disease Progression and Therapeutic Strategies.

Mathias-Machado M, Peixoto R, Moniz C, Jacome A Biomedicines. 2022; 10(8).

PMID: 36009576 PMC: 9405643. DOI: 10.3390/biomedicines10082029.

Prognostic factors for patients with anal cancer treated with conformal radiotherapy-a systematic review.

Theophanous S, Samuel R, Lilley J, Henry A, Sebag-Montefiore D, Gilbert A BMC Cancer. 2022; 22(1):607.

PMID: 35659632 PMC: 9164501. DOI: 10.1186/s12885-022-09729-4.

A Prospective Cohort Study of Biomarkers in Squamous Cell Carcinoma of the Anal Canal (SCCAC) and their Influence on Treatment Outcomes.

Moniz C, Riechelmann R, Oliveira S, Bariani G, Rivelli T, Ortega C J Cancer. 2021; 12(23):7018-7025.

PMID: 34729104 PMC: 8558650. DOI: 10.7150/jca.57678.

References

Oohira G, Yamada S, Ochiai T, Matsubara H, Okazumi S, Ando K . Growth suppression of esophageal squamous cell carcinoma induced by heavy carbon-ion beams combined with p53 gene transfer. Int J Oncol. 2004; 25(3):563-9. View

Holm R, Skovlund E, Skomedal H, Florenes V, Tanum G . Reduced expression of p21WAF1 is an indicator of malignant behaviour in anal carcinomas. Histopathology. 2001; 39(1):43-9. DOI: 10.1046/j.1365-2559.2001.01161.x. View

Bonner J, Harari P, Giralt J, Cohen R, Jones C, Sur R . Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2009; 11(1):21-8. DOI: 10.1016/S1470-2045(09)70311-0. View

Cummings B . Metastatic anal cancer: the search for cure. Onkologie. 2006; 29(1-2):5-6. DOI: 10.1159/000090747. View

Tanum G, Holm R . Anal carcinoma: a clinical approach to p53 and RB gene proteins. Oncology. 1996; 53(5):369-73. DOI: 10.1159/000227590. View

Gerdes J, Schwab U, Lemke H, STEIN H . Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31(1):13-20. DOI: 10.1002/ijc.2910310104. View

Bonin S, Pajak T, Russell A, Coia L, Paris K, Flam M . Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group. Cancer. 1999; 85(6):1226-33. View

Indinnimeo M, Cicchini C, Stazi A, Giarnieri E, Limiti M, Ghini C . nm23-H1 protein expression in anal canal carcinoma: does it correlate with prognosis?. J Surg Oncol. 2000; 74(2):163-6. DOI: 10.1002/1096-9098(200006)74:2<163::AID-JSO16>3.0.CO;2-D. View

Idogawa M, Sasaki Y, Suzuki H, Mita H, Imai K, Shinomura Y . A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells. Clin Cancer Res. 2009; 15(11):3725-32. DOI: 10.1158/1078-0432.CCR-08-2396. View

10.

Kuo K, Hsiao C, Lin C, Kuo L, Huang S, Lin M . The biomarkers of human papillomavirus infection in tonsillar squamous cell carcinoma-molecular basis and predicting favorable outcome. Mod Pathol. 2008; 21(4):376-86. DOI: 10.1038/modpathol.3800979. View

11.

Deville L, Hillion J, Segal-Bendirdjian E . Telomerase regulation in hematological cancers: a matter of stemness?. Biochim Biophys Acta. 2009; 1792(4):229-39. DOI: 10.1016/j.bbadis.2009.01.016. View

12.

Macdonald N, De la Rosa A, Steeg P . The potential roles of nm23 in cancer metastasis and cellular differentiation. Eur J Cancer. 1995; 31A(7-8):1096-100. DOI: 10.1016/0959-8049(95)00152-9. View

13.

Carr N . M30 expression demonstrates apoptotic cells, correlates with in situ end-labeling, and is associated with Ki-67 expression in large intestinal neoplasms. Arch Pathol Lab Med. 2000; 124(12):1768-72. DOI: 10.5858/2000-124-1768-MEDACC. View

14.

. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996; 348(9034):1049-54. View

15.

Zhu C, da Cunha Santos G, Ding K, Sakurada A, Cutz J, Liu N . Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008; 26(26):4268-75. DOI: 10.1200/JCO.2007.14.8924. View

16.

de Kok J, Ruers T, van Muijen G, van Bokhoven A, Willems H, Swinkels D . Real-time quantification of human telomerase reverse transcriptase mRNA in tumors and healthy tissues. Clin Chem. 2000; 46(3):313-8. View

17.

Alvarez G, Perry A, Tan B, Wang H . Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol. 2006; 19(7):942-9. DOI: 10.1038/modpathol.3800608. View

18.

Indinnimeo M, Cicchini C, Stazi A, Limiti M, Ghini C, Mingazzini P . Prognostic impact of CD31 antigen expression in anal canal carcinoma. Hepatogastroenterology. 2001; 48(41):1355-8. View

19.

Shalhoub J, Naughton P, Lau N, Tsang J, Kelly C, Leahy A . Concurrent colorectal malignancy and abdominal aortic aneurysm: a multicentre experience and review of the literature. Eur J Vasc Endovasc Surg. 2009; 37(5):544-56. DOI: 10.1016/j.ejvs.2009.01.004. View

20.

Brujan I, Margaritescu C, Simionescu C, Pirici D, Fronie A, Foarfa C . Cathepsin-D expression in breast lesion: an immunohistochemical study. Rom J Morphol Embryol. 2009; 50(1):31-9. View